# We’re on a mission to enable effective therapies to people faster.

## A novel approach to research

For the past two decades clinical research has been hindered by outdated processes and technologies leaving millions without treatments.

After struggling to access patients in her own research in rare skin diseases, Dr. Michelle Longmire set out to solve this long-standing challenge in research.

Drawing inspiration from innovation and technological advancements in other industries, Longmire rallied stakeholders, partners, and developers to launch our company, Medable, with the shared vision of radically increasing the number of effective therapies to people each year.

## Committed to science. Powered by innovation.

In order to achieve this vision, we needed to amplify the quality, reach, velocity, and cost of research.

Driven by the belief that clinical research can and should be better, we've assembled world-class scientific and product teams to continuously drive evidence-based improvements to the trial experience for all.

## The relentless pursuit of progress, together.

Human connection is at the heart of everything we do. We prioritize the personal experience of patients, caregivers, knowing that their knowledge and feedback are essential to improving clinical research. In close partnership with our network of sites, we continuously improve our platform, because we know that when they win, we all win. By designing products that are more accessible and user-friendly, we can bring life-change treatments to those who need them faster.

Together, with our clients and partners, we continue to work toward our mission and drive clinical research forward for the betterment of all.

## Accolades

## The latest from Medable

[**Medable Launches Agentic Accelerator Program to Help Life Sciences Companies Deploy Agentic AI Across Clinical Development Lifecycle**](/content/newsroom/medable-launches-agentic-accelerator-program-to-help-life-sciences-companies-deploy-agentic-ai-across-clinical-lifecycle/index.html)

_High-touch enablement helps sponsors operationalize industry-specific agents to realize value faster._

[**New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI**](/content/newsroom/new-tufts-csdd-analysis-finds-ai-agents-can-deliver-up-to-21-million-in-net-financial-value-per-drug-development-program-and-up-to-82x-roi/index.html)

Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment.

[**More than a tool: How AI agents are transforming clinical trials**](/content/knowledge-center/webinar-not-just-a-tool-how-ai-agents-become-trial-teammates/index.html)

Explore how agentic AI is transforming clinical trials by automating routine tasks and boosting team efficiency with real-world, low-risk use cases.

Speakers

Andrew Mackinnon

Jessica Dolfi

Luke Bates

## See how Agent Studio can transform your trials.

[Book a demo](/content/company/about-us#/index.html)